Clinical trials: Pulmonary Disorder
Pneumonia
CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
The aim of the study described is to measure the degree with which zinc given as adjunct therapy to standard antibiotic treatment during childhood pneumonia reduces the risk of treatment failure and the duration of the illness.
- Trial name
- NCT00148733
- Testing
- Zinc
- Where
- Nepal
- Volunteers
- 2,628 people
- Sponsor
- Centre For International Health
Non Small Cell Lung Cancer
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer.
- Trial name
- SQUIRE (NCT00981058)
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 182 sites in United States, Australia and 24 more
- Volunteers
- 1,093 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
Primary Objective: To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen.
- Trial name
- NCT00410189
- Testing
- ZD6474
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult, Breast Cancer
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Breast Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer
- Trial name
- NCT03149549
- Testing
- CX-2009
- Where
- 26 sites in United States, Netherlands and 2 more
- Volunteers
- 99 people
- Sponsor
- CytomX Therapeutics
Tetraplegia, Asthma
Exhaled Levels of Nitric Oxide
Previously it was observed that individuals with tetraplegia have reduced baseline airway caliber and exhibit non-specific airway hyperresponsiveness (AHR).
- Trial name
- NCT00753948
- Testing
- N-Nitro L-arginine-methylester (L-NAME)
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Lung Cancer, Non-Small-Cell Lung Carcinoma
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients
This study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.
- Trial name
- NCT00201825
- Testing
- Capecitabine, Docetaxel
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Tony Bekaii-Saab
Maternal Death, Maternal Infections Affecting Fetus or Newborn
Azithromycin-Prevention in Labor Use Study (A-PLUS)
Maternal and neonatal infections are among the most frequent causes of maternal and neonatal deaths, and current antibiotic strategies have not been effective in preventing many of these deaths.
- Conditions
- Maternal Death, Maternal Infections Affecting Fetus or Newborn, Neonatal SEPSIS, Maternal Sepsis During Labor
- Trial name
- NCT03871491
- Testing
- Azithromycin
- Where
- 8 sites in Bangladesh, Democratic Republic of the Congo and 5 more
- Volunteers
- 58,747 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
COVID-19, Coronavirus
Will Hydroxychloroquine Impede or Prevent COVID-19
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus…
- Conditions
- COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
- Trial name
- WHIP COVID-19 (NCT04341441)
- Testing
- Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Monitoring Visit - Baseline
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Pulmonary Disease, Chronic Obstructive
A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the safety and efficacy of a single dosage strength of GW685698/GW642444 in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00731822
- Testing
- GW685698/GW642444
- Where
- 9 sites in Norway, Sweden
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events
Background: Recent observational studies have reported possible arrhythmogenic effects with long-acting beta-agonists (LABA), while the long-acting anticholinergic tiotropium has been associated with cardiovascular and…
- Trial name
- NCT02096731
- Where
- Canada
- Volunteers
- 115,397 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Primary Objective To demonstrate that CHF 1535 pMDI is non-inferior to Symbicort® Turbohaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 24) in patients with COPD.
- Trial name
- FORSYYN (NCT03888131)
- Where
- 53 sites in China
- Volunteers
- 750 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Covid-19
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
- Trial name
- Inova-CCP (NCT04502472)
- Testing
- Convalescent plasma transfusion
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Inova Health Care Services
Pulmonary Disease, Chronic Obstructive
The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
This non-Interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with COPD patients attended at Spanish Primary Care offices.
- Trial name
- NCT03611777
- Testing
- Inhaled corticosteroid
- Where
- 169 sites in Spain
- Volunteers
- 901 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
As monotherapy for pulmonary arterial hypertension (PAH) begins to fail additional therapies are introduced. Although co-administration of sitaxsentan and sildenafil is well tolerated the controlled safety/efficacy database of…
- Trial name
- NCT00796666
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 48 sites in United States, Argentina and 16 more
- Volunteers
- 131 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
Study will assess PF-00489791 efficacy and safety in Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT00853112
- Testing
- PF-00489791, sildenafil
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities…
- Trial name
- NCT01449461
- Testing
- Brigatinib
- Volunteers
- 137 people
- Sponsor
- Ariad Pharmaceuticals
Cystic Fibrosis
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and infection. A majority of people with cystic fibrosis have large quantities of bacteria residing in their lungs.
- Trial name
- PIPE-CF (NCT01694069)
- Testing
- Piperacillin-tazobactam combination product
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- West Virginia University
COVID-19
PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients.
- Trial name
- NCT04347954
- Testing
- Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy.
- Trial name
- NCT05975905
- Testing
- Dose A KER-012, Dose B KER-012, Dose C KER-012
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 113 people
- Sponsor
- Keros Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.